HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Reneo Pharmaceuticals (NASDAQ:RPHM) and maintained a $30 price target.
October 12, 2023 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reneo Pharmaceuticals' stock has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $30.
The reiteration of a 'Buy' rating and a maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Reneo Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100